We attended the Annual Meeting of the American Society of Clinical Oncology 2017 (ASCO 2017) from June 2 to June 6 in Chicago.
After several years of huge excitement around IO this year’s meeting tone was more muted. IO is real and there are synergistic effects in combinations therapies – just as it was hoped for – but what is missing is better biomarkers in order to figure out which patients will benefit best from what treatments.
We attended the ASCO 2023 annual meeting in Chicago. After the rise of immuno-oncology, COVID-19 challenged clinical trial execution and muted patient numbers. In the last years we saw many setbacks of once promising immuno-oncology combinations trials.
What mattered this month in healthcare? Q1 reporting came to a close, and FTC action put pressure on the biopharma space and... Find out more in our monthly healthcare newsletter.
With M&A picking up, are we at a turning point for biotech? Check out our latest Kieger AG Chart of the Month Video.